
About PrognomiQ
PrognomiQ is a Healthcare company based in San Mateo (United States) founded in 2020 by Philip Ma and Omid Farokhzad. Developer of tests for the detection and treatment of cancer and other diseases. PrognomiQ has raised $102.24 million across 4 funding rounds from investors including Fidelity Investments, T. Rowe Price and Bruker. The company has 24 employees. Its chief executive, as recorded, is Philip Ma. PrognomiQ offers products and services including Multi-Omics Tests and Proteomic Data Services. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is PROGNOMIQ, INC. Its competitors include ACRO Biosystems, List Biological Laboratories and Ansh Labs; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 2020 and headquartered in San Mateo, United States, PrognomiQ operates in the health technology sector. Diagnostic tests are developed by the company to identify cancer and other diseases at early stages. Proteomic data is integrated with genomic, metabolomic, and additional health information to support detection and treatment strategies. Operations focus on advancing personalized medicine through multi-omics approaches.
- Headquarters San Mateo, United States
- Employees 24
- Founders Philip Ma, Omid Farokhzad
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website prognomiq.com
- Social LinkedIn X
- Legal Name Prognomiq, Inc.
- Total Equity Funding$102.24M (USD)
in 4 rounds
- Latest Funding Round$11.87M (USD), Series D
Jan 2026
- InvestorsFidelity Investments
& 9 more
- Employee Count24
Products & Services of PrognomiQ
PrognomiQ offers a comprehensive portfolio of products and services, including Multi-Omics Tests and Proteomic Data Services.
Enables early detection of diseases using integrated proteomics data.
Provides insights into disease mechanisms via large-scale protein analysis.
Funding Insights of PrognomiQ
PrognomiQ has successfully raised a total of $102.24M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $11.87 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $102.24M
- Total Rounds 4
- Last Round Series D β $11.87M
- First Round $46M
(Mar 2022)
- Investors Count 10
All 4 funding rounds of PrognomiQ with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
10 investors in total: 10 institutional.
Investors in PrognomiQ
PrognomiQ has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Bruker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Venture capital investments in healthcare are focused on by aMoon. | amoon.fund | |||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Early-stage tech and life-sciences firms are funded across the US. | maverickventures.com | San Francisco, United States | ||
Venture capital fund and fund of funds focused on early-stage startups | wing.vc | Palo Alto, United States | ||
Proteomics platform developed for early cancer and neurological disease detection. | 2017 | seer.bio | San Francisco, United States | |
Diversified research instrument systems are manufactured and supplied. | 1960 | bruker.com | United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
| emersoncollective.com |
Investor details for PrognomiQ
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PrognomiQ
39 people are tracked at PrognomiQ (11 in leadership, 14 in board & advisors, 14 in team); the tracked headcount is 24.
| Name | Role | Group |
|---|---|---|
Philip Ma | Co-Founder & CEO | Leadership |
Omid Farokhzad | Co-Founder | Leadership |
Bruce Wilcox | CTO | Leadership |
Bob Zawada | Senior Director Product Development | Leadership |
David Siewers | CFO | Leadership |
Joel Kaufman | Chief Financial Officer | Leadership |
Madhuvanthi Ramaiah | VP Of Product Management & PMO | Leadership |
Yi (Jimmy) Zeng | Associate Director of Mass Spectrometry | Leadership |
Nithya S Mudaliar | Head Of Clinical Operations | Leadership |
Sandra Golez Meily | Executive Assistant To Chief Executive Officer | Leadership |
Brian Koh | Chief Medical Officer | Leadership |
Tomer Berkovitz | Director | Board & advisors |
Philip Kantoff | Scientific & Clinical Advisor | Board & advisors |
Charles Cantor | Scientific Advisor | Board & advisors |
Robert Langer | Scientific Advisor | Board & advisors |
Mark Lee | Scientific & Clinical Advisor | Board & advisors |
Alfred Sandrock | Scientific & Clinical Advisor | Board & advisors |
Steven Carr | Scientific Advisor | Board & advisors |
Catherine Ball | Scientific Advisor | Board & advisors |
Ernest Fraenkel | Scientific Advisor | Board & advisors |
19 more people are available in the full profile.
Complete people profiles for PrognomiQ
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PrognomiQ
3 dated milestones of PrognomiQ across 6 years, from founding to its latest funding, stage changes and deals.
- Founded PrognomiQ is founded.
- Funding First funding round of $46.0M.
- Funding Latest funding round, Series D, of $11.9M.
Competitors of PrognomiQ
PrognomiQ has 3 listed competitors in our database, 1 of them funded. They include ACRO Biosystems, List Biological Laboratories and Ansh Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| acrobiosystems.com | 2016 | Newark, United States | 22 | Recombinant proteins are manufactured to support cancer immunotherapy efforts. | ||
| listlabs.com | 1978 | Campbell, United States | $48.4M | Specializes in the production of research reagents | ||
| anshlabs.com | 2010 | Webster, United States | 33 | Immunoassay reagents and kits are developed for life science research. |
Detailed competitors of PrognomiQ
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PrognomiQ
The website of PrognomiQ (prognomiq.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 151.6% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as PrognomiQ (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prognomiq
Complete news archive for PrognomiQ
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PrognomiQ
PrognomiQ was founded in 2020 and raised its 1st funding round 2 years after it was founded.
PrognomiQ is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Philip Ma is the CEO of PrognomiQ, as recorded in our data. They have also founded this company.
PrognomiQ is a funded company, having raised a total of $102.24M across 4 funding rounds to date. The company's 1st funding round was a Series C of $46M, raised on Mar 2022.
PrognomiQ has 24 employees.
Founded in 2020 and headquartered in San Mateo, United States, PrognomiQ operates in the health technology sector. Diagnostic tests are developed by the company to identify cancer and other diseases at early stages. Proteomic data is integrated with genomic, metabolomic, and additional health information to support detection and treatment strategies. Operations focus on advancing personalized medicine through multi-omics approaches.
PrognomiQ's top competitors include ACRO Biosystems, Ansh Labs and List Biological Laboratories.
PrognomiQ offers Multi-Omics Tests and Proteomic Data Services.
PrognomiQ has 10 investors. Key investors include Fidelity Investments, T. Rowe Price, Bruker, Seer, and Catalio Capital Management.
PrognomiQ operates through Prognomiq, Inc..
